Introduction
============

A high incidence of sleep dysfunction has been reported in patients with Parkinson's disease (PD) \[[@B1]-[@B3]\], especially in patients receiving dopaminergic agent treatment \[[@B3],[@B4]\]. PD patients with significant sleep dysfunction may indicate early progressive degeneration of the sleep centers \[[@B5]\]. Chinese medicine (CM) preparations have shown beneficial effects on aging-related symptoms \[[@B6],[@B7]\] and chronic diseases, such as PD \[[@B8]-[@B13]\], including improved nocturnal sleep disorder in PD patients \[[@B14]\].

As a CM compound for treating headache and dizziness associated with serious sleep disturbances, *Yang-Xue-Qin-Nao* granules (YXQN) attenuate cerebral microcirculatory disturbances during ischemia-reperfusion injury *in vivo*\[[@B15]\], which might improve the sleep dysfunction in PD patients. YXQN (Tianjin Tasly Pharmaceutical Co. Ltd., Tianjin, China) is a newly developed compound medicine that was approved in 1996 by the China State Food and Drug Administration for the treatment of headache and dizziness associated with cerebrovascular diseases. The granules are composed of 11 herbs: Radix angelicae sinensis (*Dang Gui*), 6.76%; Rhizoma chuanxiong (*Chuan Xiong*), 6.76%; Radix paeoniae alba (*bai shao*), 5.41%; Ramulus uncariae cum uncis (*Gou Teng*), 13.51%; Caulis spatholobi (*Ji Xue Teng*), 13.51%; Spica prunellae (*Xia Ku Cao*), 13.51%; Concha margaritifera usta (*Zhen Zhu Mu*), 13.51%; Radix rehmanniae preparata (*Di Huang*), 5.41%; Semen cassiae (*Jue Ming Zi*), 13.51%; Rhizoma corydalis yanhusuo (*Yan Hu Suo*), 6.76%; and Herba asari (*Xi Xin*), 1.35%. Available evidence from *in vitro* studies has revealed that at least six chemicals derived from these herbs exhibit antioxidant potential, inhibit neutrophil adhesion to endothelial cells and decrease infarct size and brain tissue damage \[[@B15]\]. YXQN was reported to show effects on functional and structural changes in microvessels in the cerebral cortex of gerbils induced by ischemia-reperfusion injury \[[@B15]\]. These granules might improve non-motor symptoms, such as dizziness, headache and even depression \[[@B16],[@B17]\].

This study aimed to evaluate the effects of add-on YXQN in PD patients by analyzing actigraphic measurements \[[@B18],[@B19]\]. The changes in detrended fluctuation analysis (DFA) parameters were analyzed by the actigraph records for diurnal activity (DA), evening activity (EA) and nocturnal activity (NA).

Methods
=======

Participant inclusion and exclusion criteria
--------------------------------------------

The UK Parkinson's Disease Society Brain Bank clinical diagnostic criteria were used to assess the eligibility for participation in this study. PD was defined by the presence of at least two of the four cardinal features (bradykinesia, tremor, rigidity and postural reflex abnormality). Subjects were included if they had idiopathic PD, were being treated with daytime levodopa and had at least three awakenings per night occurring at least three nights per week and attributable to PD symptoms \[[@B20]\]. Exclusion criteria were current direct dopamine agonist treatment, dementia, depression, psychosis, hallucinations, and prior intolerance to dopamine agonists or use of sleep medications. All patients were at least 40 years of age, were evaluated in the middle of their levodopa dose cycle at maximal mobility ('on') for the severity of parkinsonism and signed informed consent before participation. The study was approved by The Ethics Committee of Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, and was performed in accordance with the principles outlined in the Declaration of Helsinki.

Randomization, masking and drug administration
----------------------------------------------

An unmasked pharmacist generated randomization codes using an Excel (Microsoft Office) random number generator (Microsoft, USA) in blocks of two and four participants. Kits were given sequential numbers that corresponded to the randomization key and were maintained in a secure location. When randomized, each successive participant was assigned by an electronic Clinical Trial Management System to the next numbered kit in sequence at each site. YXQN and the placebo granules (one-tenth active compound of YXQN with a flavor enhancer) were manufactured by the same pharmaceutical company (Tianjin Tasly Pharmaceutical Co. Ltd., China), and the shape and color of both types of granules were identical (non-distinguishable by the participants). Tablets containing YXQN (4 g) or placebo granules (4 g) were packaged into kits of several blister packs (1 week of treatment per pack). All participants and study personnel were blinded to the treatment assignment. The PD participants were randomized into either a YXQN group or a placebo group, and were required to take the granules three times per day for 12 consecutive weeks. Anti-parkinsonian drug administration was not changed throughout the study (Table [1](#T1){ref-type="table"}). The participants were not treated by any other complementary and alternative treatments, such as other CM, *Tai Chi* exercise or acupuncture. The control group consisted of participants with one or more conditions such as idiopathic hypertension, chronic nephritis, chronic inflammatory demyelinating polyneuropathy and coronary heart disease, but no sleep disturbance or PD, who were diagnosed by physicians and neurologists. The control participants were invited to participate in a 1-week consecutive recording session to evaluate their sleep characteristics. Their activities and DFA parameters were recorded for comparison, because we found that the scores of the healthy controls changed only very slightly after 1 year (Weidong Pan, unpublished observation).

###### 

Subject characteristics

  **Subjects**                        **Control group (n = 35)**   **Placebo group (n = 30)**   **YXQN group (n = 31)**   ***P*value**
  ----------------------------------- ---------------------------- ---------------------------- ------------------------- --------------
  Age (yr)                            66.8 ± 7.7                   67.1 ± 10.2                  68.6 ± 9.2                0.89
  Men/Women                           21/14                        19/11                        18/13                     \-
  Disease duration                    \-                           6.1 ± 4.9                    5.9 ± 4.7                 0.17
  UPDRS score                         \-                           37.59 ± 10.51                38.35 ± 6.78              0.23
  Levodopa/DCI (mg/day)               \-                           412.5 ± 162.8                421.3 ± 142.9             0.65
  Pramipexole(mg/day)                 \-                           1.11 ± 0.39                  1.03 ± 0.78               0.08
  Entacapone (mg/day)                 \-                           198.28 ± 88.47               203.67 ± 78.38            0.12
  Selegiline hydrochloride (mg/day)   \-                           8.33 ± 6.94                  8.21 ± 3.76               0.26
  Adamantatamine (mg/day)             \-                           118.73 ± 96.59               116.31 ± 89.6             0.19
  Artane hydrochloride (mg/day)       \-                           4.82 ± 2.91                  4.65 ± 2.36               0.08

Equipment and data analysis
---------------------------

Each participant wore an actigraph which was a small watch-type activity monitor equipped with a computer (*MicroMini-Motionlogger*; Ambulatory Monitoring Inc., USA), on the wrist of their non-dominant hand for 6 consecutive days in the series time windows (4 weeks each) during the 16-week observation period. Zero-crossing counts were recorded every minute by the actigraph to quantify the level of physical activity. The data were transmitted to a computer and the activity scores were plotted for 3 consecutive days to determine the daily profiles and biological rhythms of each participant. The data acquired from the actigraph were categorized into DA (between 6 a.m. and 6 p.m.), EA (between 6 p.m. and 9 p.m.) and NA (between 9 p.m. and 6 a.m.). Discontinuous data were combined through an integrative method as follows. We divided the difference between the two connecting terminals of the two data into four quarters, made the connection into an oblique line (it was a broken line before integration) to avoid connecting errors, and connected all the pieces of data into one continuous sequence for fluctuation analysis \[[@B18]\]. Subsequently, we analyzed the DFA value α to evaluate the relationships between time scales and magnitudes of fluctuation (standard deviations: SDs) within each time scale \[[@B21],[@B22]\]. More correlated signals represented a greater growth of the fluctuation magnitude with increasing time scale or length of data windows \[[@B18]\]. The outcome measures were assessed at baseline and every 4 weeks during the 16-week intervention.

Clinical evaluation
-------------------

The unified Parkinson's disease rating scale (UPDRS) score \[[@B23]\] and Parkinson\'s disease sleep scale (PDSS) score \[[@B24]\] were evaluated for all participants at week 0 (baseline) and at weeks 4, 8, 12 and 16 by neurologists who were blinded to the test granules. The PDSS score in the control group was evaluated once on the first day of the recording week.

Statistical analysis
--------------------

Repeated-measure ANOVAs were conducted to test the differences among changes in outcomes at baseline and every 4 weeks for 16 weeks. When a significant difference was detected, a *post hoc* test (Bonferroni test) was conducted between the YXQN group and the placebo group to compare the UPDRS total scores, the α values of DA, EA and NA, and the changes in the PDSS scores. The differences at baseline between the control group and the YXQN group, and between the control group and the placebo group were analyzed by *t*-tests. A significant difference was defined as *P* \< 0.05. SPSS for Windows version 17.0 (SPSS China, China) was used for statistical analyses. All data were expressed as the mean ± SD.

Results
=======

Eighty-two idiopathic PD patients at the Department of Neurology of Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine were recruited, and 70 patients who met the criteria were enrolled. Five PD participants in the YXQN group withdrew from the study for drug-related reasons: two participants experienced nausea and three were unable to tolerate the bitter taste of YXQN. Four participants in the placebo group dropped out: one participant was unable to tolerate the bitter taste of placebo, two participants dropped out because of inefficacy and one dropped out through a conflict with other CM preparations prescribed for concomitant diseases.

A total of 61 PD participants completed the trial, and were randomized into the YXQN group (n = 31) and the placebo group (n = 30) (Table [1](#T1){ref-type="table"}). All control participants (n = 35) completed 1 week of recording. No differences in age or sex distribution were observed among the three groups. No differences in PD duration, UPDRS total score, PDSS score, α values of DFA for DA, EA and NA or dose of levodopa at baseline were observed between the YXQN group and the placebo group (Table [1](#T1){ref-type="table"}).

NA was decreased after the additional treatment in the YXQN group (Figure [1](#F1){ref-type="fig"}B and C). The improvements in NA in the YXQN group after continuous daily treatment for 12 weeks were similar to those in the control group (Figure [1](#F1){ref-type="fig"}A and C). In both the YXQN group and the placebo group, the α values of DFA for DA, EA and NA, and the PDSS score at baseline were significantly different from those in the control group (Figure [2](#F2){ref-type="fig"}). The α values of DA in the YXQN group decreased slightly during the 16-week observation period (Figure [2](#F2){ref-type="fig"}A). The α values for EA in the YXQN group were decreased at weeks 4, 12 and 16 compared with the placebo group (Figure [2](#F2){ref-type="fig"}B). Compared with the placebo group, the YXQN group had significantly increased α values for NA at weeks 8, 12 and 16, and increased PDSS values (Figure [2](#F2){ref-type="fig"}C and D). The better UPDRS scores were observed in the YXQN group at the end of the intervention compared with the placebo group, but there were no significant changes compared with baseline in either group of PD participants (Table [2](#T2){ref-type="table"}). The improvements in the α values and PDSS score in the YXQN group were similar to those in the control group, and the effects in the YXQN group were maintained for 4 weeks (Figure [2](#F2){ref-type="fig"}). No serious adverse events were observed.

![**Daily profiles of actigraph counts showing the biological rhythm before and after granule ingestion in the control group (A), placebo group (B), and*Yang-Xue Qing-Nao*granule (YXQN) group (C).**The light green color indicates sleep duration.](1749-8546-8-14-1){#F1}

![**Mean changes in*α*values of detrended fluctuation analysis (DFA) in diurnal activity (DA) value (A), evening activity (EA) value (B), diurnal activity (DA) value (C) and Parkinson's disease sleep scale (PDSS) score (D) at baseline, and at weeks 4, 8, 12 and 16.** Black circles indicate the *Yang-Xue Qing-Nao*granule (YXQN) group, white circles indicate the placebo group and white squares indicate the control group. \**P*\< 0.05, *vs.*baseline; ^☆^*P*\< 0.05, *vs.*placebo group; ^\#^*P*\< 0.05, ^\#\#^*P*\< 0.01, *vs.*YXQN group or placebo group.](1749-8546-8-14-2){#F2}

###### 

Changes in detrended fluctuation analysis (DFA) values, Parkinson's disease sleep scale (PDSS) and unified Parkinson's disease rating scale (UPDRS)

  **Variable**    **Mean changes from baseline (95%CI)**   **Between group difference (96%CI)**                           
  --------------- ---------------------------------------- -------------------------------------- ----------------------- -------
  α value of DA                                                                                                            
    Week 8        −0.9 \[−1.1 to −0.7\]                    −0.2 \[−0.3 to 0.1\]                   −0.7 \[−1.0 to −0.8\]   0.056
    Week 12       −1.0 \[−1.2 to −0.7\]                    −0.1 \[−0.3 to 0.2\]                   −0.8 \[−1.1 to −0.7\]   0.051
    Week 16       −0.9 \[−1.1 to −0.6\]                    −0.2 \[−0.2 to 0.3\]                   −0.9 \[−1.1 to −0.7\]   0.072
  α value of EA                                                                                                            
    Week 8        −1.1 \[−1.4 to −0.6\]                    −0.1 \[−0.1 to 0.2\]                   −1.0 \[−1.3 to −0.5\]   0.048
    Week 12       −0.9 \[−1.0 to −0.6\]\*                  0.1 \[−0.3 to 0.4\]                    −1.1 \[−1.6 to −0.7\]   0.036
    Week 16       −0.9 \[−1.1 to −0.7\]\*                  −0.2 \[−0.4 to 0.3\]                   −0.9 \[−1.3 to −0.8\]   0.041
  α value of NA                                                                                                            
    Week 8        1.0 \[0.8 to 1.6\]\*                     −0.3 \[−0.6 to 0.4\]                   1.1 \[0.7 to 1.5\]      0.017
    Week 12       1.1 \[0.7 to 1.5\]\*                     −0.1 \[−0.5 to 0.5\]                   1.0 \[0.6 to 1.4\]      0.038
    Week 16       0.9 \[0.6 to 1.7\]\*                     −0.2 \[−0.5 to 0.4\]                   0.9 \[0.7 to 1.6\]      0.042
  PDSS score                                                                                                               
    Week 8        12.1 \[7.6 to 13.7\]\*                   2.9 \[−4.1 to 9.7\]                    10.7 \[6.9 to 16.5\]    0.026
    Week 12       11.9 \[7.1 to 14.2\]\*                   3.3 \[−6.6 to 7.3\]                    9.8 \[8.7 to 15.9\]     0.029
    Week 16       9.8 \[7.0 to 14.6\]\*                    3.2 \[−4.9 to 5.1\]                    9.9 \[7.4 to 17.6\]     0.048
  UPDRS score                                                                                                              
    Week 8        −6.6 \[−11.4 to −2.8\]                   −1.7 \[−2.8 to 3.9\]                   −4.9 \[−6.7 to −2.7\]   0.076
    Week 12       −5.7 \[−10.8 to −1.9\]                   −0.9 \[−1.7 to 2.1\]                   −5.1 \[−8.3 to −2.4\]   0.069
    Week 16       −5.2 \[−8.9 to −2.1\]                    2.1 \[−4.2 to 6.1\]                    −4.6 \[−7.5 to −3.1\]   0.153

\*: *P* \< 0.05, compared with baseline.

Discussion
==========

Herbal treatments may influence PD symptoms and the effectiveness of dopaminergic therapy \[[@B25]\]. The improved NA associated with YXQN, but not with nocturnal levodopa, may be attributed to differences in the pharmacologic actions on dopamine receptor subtypes or the effects of YXQN on other neurotransmitter systems \[[@B15]\]. The UPDRS scores improved slightly after YXQN administration (Table [2](#T2){ref-type="table"}), and the observed benefits might be caused by the sleep effects, rather than direct motor effects, in patients with PD.

Currently, complementary and alternative treatments are becoming more effective for the treatment of chronic disorders, such as dementia, sleep disorder, mood disorders, high blood pressure and anxiety \[[@B26]-[@B31]\]. However, there is no reliable quantitative and objective equipment to evaluate the effects. Several studies have demonstrated the utility of actigraphs \[[@B14],[@B18]-[@B20]\] and their application in PD to assess disease severity, NA and circadian rest-activity rhythm with aging and Alzheimer's disease \[[@B32]\], and to distinguish tremors from soma activity in PD patients \[[@B33]\]. Although actigraphs cannot distinguish between NA owing to wakefulness and NA caused by other nocturnal sleep disturbances, such as REM sleep behavior disorder, periodic limb movements or sleep apnea, none of the latter effects are caused or worsened by dopamine treatment. Nocturnal sleep disturbance may arise from these symptoms \[[@B2]-[@B4]\], and demonstration of improvements may indicate that the sleep disturbance can be treated by alternative therapies such as YXQN. The exact mechanisms of the effects of YXQN on REM sleep behavior disorder, periodic limb movements or sleep apnea remain to be determined.

In this study, administration of YXQN three times per day for 12 weeks was effective for improving EA and sleep dysfunction in PD participants, and these improvements were maintained for 16 weeks. A lower α value of DFA indicates a higher activity ability during the diurnal period, while a higher α value of DFA reflects a lower activity ability during the nocturnal period \[[@B18],[@B21],[@B22]\]. No treatment-related adverse events, such as hypotension, abnormal liver and/or renal function, diarrhea or coagulation defects, were observed in the study participants, indicating that YXQN is likely to be a safe therapy for PD patients with sleep dysfunction.

Conclusion
==========

YXQN improved the DFA parameters, and PDSS and UPDRS scores in PD participants.
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